(UroToday.com) In this plenary session, Dr. William Thomas Lowrance summarized the 2021 AUA/ASTRO/SUO guidelines on advanced prostate cancer, with key take-home points highlighted. The full 2 part guidelines1,2 can be found online at They are also published in the Journal of Urology.
(UroToday.com) In this study by Benjamin Lowentritt, he evaluates the real-world effectiveness and treatment adherence of apalutamide in men with non-metastatic castration-resistant prostate cancer (cM0 CRPC / nmCRPC). Based on the SPARTAN trial, apalutamide was approved for use in conjunction with androgen deprivation therapy (ADT) for men with cM0 CRPC.
» Practice-changing data presented at ESMO Congress 2021 proves oncology has recovered from pan-demic-related setbacks» Research shows cancer patients must continue to be prioritised as incidence and mortality expected to rise further» ESMO launches International Cancer Foundation to make the best cancer care accessible to patients worldwide San Francisco, CA (UroToday.com) — ESMO Congress 2021, President Solange Peters announced […]
(UroToday.com) The American Urologic Association (AUA) annual meeting’s evolving landscape of advanced prostate cancer treatment session included a talk by Dr. Joshua Lang discussing the role of chemotherapy and treatment sequencing in patients with mCRPC. Dr. Lang notes that there are a multitude of agents available, with many different sequence options:
Background: Oxidative stress is related to oncogenic transformation in kidney renal clear cell carcinoma (KIRC). We intended to identify a prognostic antioxidant gene signature and investigate its relationship with immune infiltration in KIRC.
In recent years, Controlling Nutritional Status (CONUT) Score has become widely recognized as a novel index to evaluate the survival in urological neoplasms patients, especially with renal cell carcinoma (RCC) and upper tract urothelial carcinoma (UTUC).
High mortality of prostate cancer patients is primarily due to metastasis. Understanding the mechanisms controlling metastatic processes remains essential to develop novel therapies designed to prevent the progression from localized disease to metastasis.
Many factors are implicated in the potential ‘under-treatment’ of prostate cancer but little is known about the between-hospital variation. The National Prostate Cancer Audit (NPCA) database was used to identify high-risk localised or locally advanced prostate cancer patients in England, between January 2014 and December 2017, and the treatments received.
Predict Prostate is a freely available online personalised risk communication tool for men with nonmetastatic prostate cancer. Its accuracy has been assessed in multiple validation studies, but its clinical impact among patients has not hitherto been assessed.
To evaluate the use of 3D computed aided designs and 3D-printed models as pre-operative planning tools for urologists, in addition to radiologist interpreted mp-MRIS, prior to radical prostatectomy procedures.
